TP53 and acute myeloid leukemia: However, APR-246 as a triple therapy, coupled with venetoclax and azacitidine, is also undergoing phase I studies (NCT04214860) in patients with TP53 mutation containing AML that is either untreated or have been through prior therapies with azacitidine or decitabine [56,57].